710 results on '"Chapman, Paul B."'
Search Results
2. A General Approach to Patients Presenting With Locally Advanced or Distant Metastatic Disease
- Author
-
Smithy, James W. and Chapman, Paul B.
- Published
- 2024
- Full Text
- View/download PDF
3. The State of Melanoma: Emergent Challenges and Opportunities
- Author
-
Atkins, Michael B, Curiel-Lewandrowski, Clara, Fisher, David E, Swetter, Susan M, Tsao, Hensin, Aguirre-Ghiso, Julio A, Soengas, Maria S, Weeraratna, Ashani T, Flaherty, Keith T, Herlyn, Meenhard, Sosman, Jeffrey A, Tawbi, Hussein A, Pavlick, Anna C, Cassidy, Pamela B, Chandra, Sunandana, Chapman, Paul B, Daud, Adil, Eroglu, Zeynep, Ferris, Laura K, Fox, Bernard A, Gershenwald, Jeffrey E, Gibney, Geoffrey T, Grossman, Douglas, Hanks, Brent A, Hanniford, Douglas, Hernando, Eva, Jeter, Joanne M, Johnson, Douglas B, Khleif, Samir N, Kirkwood, John M, Leachman, Sancy A, Mays, Darren, Nelson, Kelly C, Sondak, Vernon K, Sullivan, Ryan J, Merlino, Glenn, and Foundation, on behalf of the Melanoma Research
- Subjects
Prevention ,Cancer ,Biomedical Research ,COVID-19 ,Humans ,Medical Oncology ,Melanoma ,Practice Guidelines as Topic ,SARS-CoV-2 ,Skin Neoplasms ,Melanoma Research Foundation ,Oncology and Carcinogenesis ,Oncology & Carcinogenesis - Abstract
Five years ago, the Melanoma Research Foundation (MRF) conducted an assessment of the challenges and opportunities facing the melanoma research community and patients with melanoma. Since then, remarkable progress has been made on both the basic and clinical research fronts. However, the incidence, recurrence, and death rates for melanoma remain unacceptably high and significant challenges remain. Hence, the MRF Scientific Advisory Council and Breakthrough Consortium, a group that includes clinicians and scientists, reconvened to facilitate intensive discussions on thematic areas essential to melanoma researchers and patients alike, prevention, detection, diagnosis, metastatic dormancy and progression, response and resistance to targeted and immune-based therapy, and the clinical consequences of COVID-19 for patients with melanoma and providers. These extensive discussions helped to crystalize our understanding of the challenges and opportunities facing the broader melanoma community today. In this report, we discuss the progress made since the last MRF assessment, comment on what remains to be overcome, and offer recommendations for the best path forward.
- Published
- 2021
4. Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials
- Author
-
Hauschild, Axel, Ascierto, Paolo A, Schadendorf, Dirk, Grob, Jean Jacques, Ribas, Antoni, Kiecker, Felix, Dutriaux, Caroline, Demidov, Lev V, Lebbé, Céleste, Rutkowski, Piotr, Blank, Christian U, Gutzmer, Ralf, Millward, Michael, Kefford, Richard, Haas, Tomas, D'Amelio, Anthony, Gasal, Eduard, Mookerjee, Bijoyesh, and Chapman, Paul B
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Cancer ,Clinical Research ,Clinical Trials and Supportive Activities ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Adult ,Aged ,Aged ,80 and over ,Antineoplastic Agents ,Dacarbazine ,Disease Progression ,Female ,Follow-Up Studies ,Humans ,Imidazoles ,Male ,Melanoma ,Middle Aged ,Oximes ,Patient Selection ,Progression-Free Survival ,Proto-Oncogene Proteins B-raf ,Skin Neoplasms ,Time Factors ,Young Adult ,BRAF ,Dabrafenib ,Metastatic ,Long-term outcomes ,Public Health and Health Services ,Oncology & Carcinogenesis ,Oncology and carcinogenesis - Abstract
BackgroundPrevious analyses of BREAK-2 and BREAK-3 showed that durable outcomes lasting ≥3 years are achievable with dabrafenib in some patients with BRAF V600-mutant metastatic melanoma (MM); however, additional follow-up is needed to fully characterise the long-term impact of dabrafenib in these patients.MethodsBREAK-2 was a single-arm phase 2 study evaluating dabrafenib in treatment-naive or previously treated BRAF V600E/K-mutant MM. BREAK-3, a randomised (3:1) phase 3 study, assessed dabrafenib versus dacarbazine in previously untreated unresectable or metastatic BRAF V600E-mutant melanoma. Five-year analyses were performed.ResultsAll BREAK-2 patients (N = 92 [V600E, n = 76; V600K, n = 16]) discontinued treatment by the data cutoff. Median follow-up was 13.0 months. In BRAF V600E patients, 5-year progression-free survival (PFS) and overall survival (OS) were 11% and 20%, respectively. Subsequent immunotherapy was received by 22% of patients. In BREAK-3, median follow-up was 17.0 and 12.0 months in the dabrafenib (n = 187) and dacarbazine (n = 63) arms, respectively. Thirty-seven patients (59%) receiving dacarbazine crossed over to dabrafenib following disease progression as per protocol. Five-year PFS was 12% in the dabrafenib arm; all dacarbazine-arm patients progressed or were censored by 5 years. Dabrafenib improved PFS versus dacarbazine, regardless of baseline lactate dehydrogenase levels. Five-year OS rates were 24% and 22% in the dabrafenib and dacarbazine arms, respectively. Subsequent therapy in each arm included anti-CTLA-4 (dabrafenib [24%] and dacarbazine [24%]) and/or anti-PD-1 (8% and 2%) treatment. No new safety signals were observed.Conclusions and relevanceThese data, representing extended follow-up for dabrafenib monotherapy, demonstrate that durable benefit lasting ≥5 years is achievable in a subset of patients.Trial registrationClinicalTrials.gov (BREAK-2, NCT01153763; BREAK-3, NCT01227889).
- Published
- 2020
5. Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib–treated Patients with BRAFV600-mutated Metastatic Melanoma
- Author
-
Yan, Yibing, Wongchenko, Matthew J, Robert, Caroline, Larkin, James, Ascierto, Paolo A, Dréno, Brigitte, Maio, Michele, Garbe, Claus, Chapman, Paul B, Sosman, Jeffrey A, Shi, Zhen, Koeppen, Hartmut, Hsu, Jessie J, Chang, Ilsung, Caro, Ivor, Rooney, Isabelle, McArthur, Grant A, and Ribas, Antoni
- Subjects
Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Immunology ,Human Genome ,Genetics ,Biotechnology ,Cancer ,Aetiology ,2.1 Biological and endogenous factors ,Alleles ,Antineoplastic Combined Chemotherapy Protocols ,Azetidines ,Biomarkers ,Tumor ,Clinical Trials ,Phase II as Topic ,Clinical Trials ,Phase III as Topic ,Gene Expression Profiling ,Genomics ,Humans ,Melanoma ,Mutation ,Piperidines ,Proto-Oncogene Proteins B-raf ,Randomized Controlled Trials as Topic ,Retrospective Studies ,Treatment Outcome ,Vemurafenib ,Exome Sequencing ,Oncology & Carcinogenesis ,Clinical sciences ,Oncology and carcinogenesis - Abstract
PurposePrevious investigations identified transcriptional signatures associated with innate resistance to anti-programmed cell death protein 1 therapy in melanoma. This analysis aimed to increase understanding of the role of baseline genetic features in the variability of response to BRAF and MEK inhibitor therapy for BRAF V600-mutated metastatic melanoma.Patients and methodsThis exploratory analysis compared genomic features, using whole-exome and RNA sequencing, of baseline tumors from patients who had complete response versus rapid progression (disease progression at first postbaseline assessment) on treatment with cobimetinib combined with vemurafenib or vemurafenib alone. Associations of gene expression with progression-free survival or overall survival were assessed by Cox proportional hazards modeling.ResultsWhole-exome sequencing showed that MITF and TP53 alterations were more frequent in tumors from patients with rapid progression, while NF1 alterations were more frequent in tumors from patients with complete response. However, the low frequency of alterations in any one gene precluded their characterization as drivers of response/resistance. Analysis of RNA profiles showed that expression of immune response-related genes was enriched in tumors from patients with complete response, while expression of keratinization-related genes was enriched in tumors from patients who experienced rapid progression.ConclusionsThese findings suggest that enriched immune infiltration might be a shared feature favoring response to both targeted and immune therapies, while features of innate resistance to targeted and immune therapies were distinct.
- Published
- 2019
6. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis
- Author
-
McQuade, Jennifer L, Daniel, Carrie R, Hess, Kenneth R, Mak, Carmen, Wang, Daniel Y, Rai, Rajat R, Park, John J, Haydu, Lauren E, Spencer, Christine, Wongchenko, Matthew, Lane, Stephen, Lee, Dung-Yang, Kaper, Mathilde, McKean, Meredith, Beckermann, Kathryn E, Rubinstein, Samuel M, Rooney, Isabelle, Musib, Luna, Budha, Nageshwar, Hsu, Jessie, Nowicki, Theodore S, Avila, Alexandre, Haas, Tomas, Puligandla, Maneka, Lee, Sandra, Fang, Shenying, Wargo, Jennifer A, Gershenwald, Jeffrey E, Lee, Jeffrey E, Hwu, Patrick, Chapman, Paul B, Sosman, Jeffrey A, Schadendorf, Dirk, Grob, Jean-Jacques, Flaherty, Keith T, Walker, Dana, Yan, Yibing, McKenna, Edward, Legos, Jeffrey J, Carlino, Matteo S, Ribas, Antoni, Kirkwood, John M, Long, Georgina V, Johnson, Douglas B, Menzies, Alexander M, and Davies, Michael A
- Subjects
Clinical Research ,Obesity ,Cancer ,Clinical Trials and Supportive Activities ,Nutrition ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Good Health and Well Being ,Adolescent ,Adult ,Aged ,Aged ,80 and over ,Antineoplastic Agents ,Immunological ,Antineoplastic Combined Chemotherapy Protocols ,Body Mass Index ,Female ,Humans ,Male ,Melanoma ,Middle Aged ,Molecular Targeted Therapy ,Progression-Free Survival ,Protective Factors ,Randomized Controlled Trials as Topic ,Retrospective Studies ,Risk Assessment ,Risk Factors ,Skin Neoplasms ,Time Factors ,Treatment Outcome ,Young Adult ,Oncology and Carcinogenesis ,Oncology & Carcinogenesis - Abstract
BackgroundObesity has been linked to increased mortality in several cancer types; however, the relation between obesity and survival outcomes in metastatic melanoma is unknown. The aim of this study was to examine the association between body-mass index (BMI) and progression-free survival or overall survival in patients with metastatic melanoma who received targeted therapy, immunotherapy, or chemotherapy.MethodsThis retrospective study analysed independent cohorts of patients with metastatic melanoma assigned to treatment with targeted therapy, immunotherapy, or chemotherapy in randomised clinical trials and one retrospective study of patients treated with immunotherapy. Patients were classified according to BMI, following the WHO definitions, as underweight, normal, overweight, or obese. Patients without BMI and underweight patients were excluded. The primary outcomes were the associations between BMI and progression-free survival or overall survival, stratified by treatment type and sex. We did multivariable analyses in the independent cohorts, and combined adjusted hazard ratios in a mixed-effects meta-analysis to provide a precise estimate of the association between BMI and survival outcomes; heterogeneity was assessed with meta-regression analyses. Analyses were done on the predefined intention-to-treat population in the randomised controlled trials and on all patients included in the retrospective study.FindingsThe six cohorts consisted of a total of 2046 patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy between Aug 8, 2006, and Jan 15, 2016. 1918 patients were included in the analysis. Two cohorts containing patients from randomised controlled trials treated with targeted therapy (dabrafenib plus trametinib [n=599] and vemurafenib plus cobimetinib [n=240]), two cohorts containing patients treated with immunotherapy (one randomised controlled trial of ipilimumab plus dacarbazine [n=207] and a retrospective cohort treated with pembrolizumab, nivolumab, or atezolizumab [n=331]), and two cohorts containing patients treated with chemotherapy (two randomised controlled trials of dacarbazine [n=320 and n=221]) were classified according to BMI as normal (694 [36%] patients), overweight (711 [37%]), or obese (513 [27%]). In the pooled analysis, obesity, compared with normal BMI, was associated with improved survival in patients with metastatic melanoma (average adjusted hazard ratio [HR] 0·77 [95% CI 0·66-0·90] for progression-free survival and 0·74 [0·58-0·95] for overall survival). The survival benefit associated with obesity was restricted to patients treated with targeted therapy (HR 0·72 [0·57-0·91] for progression-free survival and 0·60 [0·45-0·79] for overall survival) and immunotherapy (HR 0·75 [0·56-1·00] and 0·64 [0·47-0·86]). No associations were observed with chemotherapy (HR 0·87 [0·65-1·17, pinteraction=0·61] for progression-free survival and 1·03 [0·80-1·34, pinteraction=0·01] for overall survival). The association of BMI with overall survival for patients treated with targeted and immune therapies differed by sex, with inverse associations in men (HR 0·53 [0·40-0·70]), but no associations observed in women (HR 0·85 [0·61-1·18, pinteraction=0·03]).InterpretationOur results suggest that in patients with metastatic melanoma, obesity is associated with improved progression-free survival and overall survival compared with those outcomes in patients with normal BMI, and that this association is mainly seen in male patients treated with targeted or immune therapy. These results have implications for the design of future clinical trials for patients with metastatic melanoma and the magnitude of the benefit found supports further investigation of the underlying mechanism of these associations.FundingASCO/CCF Young Investigator Award, ASCO/CCF Career Development Award, MD Anderson Cancer Center (MDACC) Melanoma Moonshot Program, MDACC Melanoma SPORE, and the Dr Miriam and Sheldon G Adelson Medical Research Foundation.
- Published
- 2018
7. Dual MEK/AKT inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS-mutant and wild-type melanoma.
- Author
-
Algazi, Alain P, Esteve-Puig, Rosaura, Nosrati, Adi, Hinds, Brian, Hobbs-Muthukumar, Adele, Nandoskar, Prachi, Ortiz-Urda, Susana, Chapman, Paul B, and Daud, Adil
- Subjects
Humans ,Melanoma ,Skin Neoplasms ,Diamines ,Pyrazoles ,Pyridones ,Pyrimidinones ,GTP Phosphohydrolases ,MAP Kinase Kinase 1 ,Membrane Proteins ,Protein Kinase Inhibitors ,Treatment Outcome ,Survival Rate ,Cohort Studies ,Mutation ,Adult ,Aged ,Aged ,80 and over ,Middle Aged ,Female ,Male ,Proto-Oncogene Proteins c-akt ,Young Adult ,AKT ,NRAS ,GSK2141795 ,MEK ,melanoma ,trametinib ,wild type ,Cancer ,Clinical Research ,AKT ,NRAS ,Biological Sciences ,Medical and Health Sciences ,Dermatology & Venereal Diseases - Abstract
Aberrant MAPK and PI3K pathway signaling may drive the malignant phenotype in NRAS-mutant and BRAFWT NRASWT metastatic melanoma. To target these pathways, NRAS-mutant and BRAFWT NRASWT patients received oral trametinib at 1.5 mg daily and GSK2141795 at 50 mg daily in a two-cohort Simon two-stage design. Participants had adequate end-organ function and no more than two prior treatment regimens. Imaging assessments were performed at 8-week intervals. A total of 10 NRAS-mutant and 10 BRAFWT NRASWT patients were enrolled. No objective responses were noted in either cohort. The median PFS and OS were 2.3 and 4.0 months in the NRAS-mutant cohort and 2.8 and 3.5 months in the wild-type cohort. Grade 3 and grade 4 adverse events, primarily rash, were observed in 25% of patients. We conclude that the combination of trametinib and GSK2141795 does not have significant clinical activity in NRAS-mutant or BRAFWT NRASWT melanoma.
- Published
- 2018
8. Vemurafenib in patients with BRAF(V600) mutation-positive meta-static melanoma: final overall survival results of the BRIM-3 study
- Author
-
Chapman, Paul B, Robert, Caroline, Larkin, James, Haanen, John B, Ribas, Antoni, Hogg, David, Hamid, Omid, Ascierto, Paolo Antonio, Testori, Alessandro, Lorigan, Paul, Dummer, Reinhard, Sosman, Jeffrey A, Flaherty, Keith T, Yue, Huibin, Coleman, Shelley, Caro, Ivor, Hauschild, Axel, and McArthur, Grant A
- Subjects
Immunology ,Medical and Health Sciences - Published
- 2016
9. Melanoma and immunotherapy bridge 2015
- Author
-
Nanda, Vashisht GY, Peng, Weiyi, Hwu, Patrick, Davies, Michael A, Ciliberto, Gennaro, Fattore, Luigi, Malpicci, Debora, Aurisicchio, Luigi, Ascierto, Paolo Antonio, Croce, Carlo M, Mancini, Rita, Spranger, Stefani, Gajewski, Thomas F, Wang, Yangyang, Ferrone, Soldano, Vanpouille-Box, Claire, Wennerberg, Erik, Pilones, Karsten A, Formenti, Silvia C, Demaria, Sandra, Tang, Haidong, Wang, Yang, Fu, Yang-Xin, Dummer, Reinhard, Puzanov, Igor, Tarhini, Ahmad, Chauvin, Joe-Marc, Pagliano, Ornella, Fourcade, Julien, Sun, Zhaojun, Wang, Hong, Sanders, Cindy, Kirkwood, John M, Chen, Tseng-hui Timothy, Maurer, Mark, Korman, Alan J, Zarour, Hassane M, Stroncek, David F, Huber, Veronica, Rivoltini, Licia, Thurin, Magdalena, Rau, Tilman, Lugli, Alessandro, Pagès, Franck, Camarero, Jorge, Sancho, Arantxa, Jommi, Claudio, de Coaña, Yago Pico, Wolodarski, Maria, Yoshimoto, Yuya, Gentilcore, Giusy, Poschke, Isabel, Masucci, Giuseppe V, Hansson, Johan, Kiessling, Rolf, Scognamiglio, Giosuè, Sabbatino, Francesco, Marino, Federica Zito, Anniciello, Anna Maria, Cantile, Monica, Cerrone, Margherita, Scala, Stefania, D’alterio, Crescenzo, Ianaro, Angela, Cirin, Giuseppe, Liguori, Giuseppina, Bott, Gerardo, Chapman, Paul B, Robert, Caroline, Larkin, James, Haanen, John B, Ribas, Antoni, Hogg, David, Hamid, Omid, Testori, Alessandro, Lorigan, Paul, Sosman, Jeffrey A, Flaherty, Keith T, Yue, Huibin, Coleman, Shelley, Caro, Ivor, Hauschild, Axel, McArthur, Grant A, Sznol, Mario, Callahan, Margaret K, Kluger, Harriet, Postow, Michael A, Gordan, RuthAnn, Segal, Neil H, Rizvi, Naiyer A, Lesokhin, Alexander, Atkins, Michael B, Burke, Matthew M, Ralabate, Amanda, Rivera, Angel, Kronenberg, Stephanie A, Agunwamba, Blessing, Ruisi, Mary, Horak, Christine, and Jiang, Joel
- Subjects
Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Immunology ,Clinical Research ,Cancer ,Good Health and Well Being ,Medical and Health Sciences ,Biomedical and clinical sciences ,Health sciences - Abstract
MELANOMA BRIDGE 2015 KEYNOTE SPEAKER PRESENTATIONS Molecular and immuno-advances K1 Immunologic and metabolic consequences of PI3K/AKT/mTOR activation in melanoma Vashisht G. Y. Nanda, Weiyi Peng, Patrick Hwu, Michael A. Davies K2 Non-mutational adaptive changes in melanoma cells exposed to BRAF and MEK inhibitors help the establishment of drug resistance Gennaro Ciliberto, Luigi Fattore, Debora Malpicci, Luigi Aurisicchio, Paolo Antonio Ascierto, Carlo M. Croce, Rita Mancini K3 Tumor-intrinsic beta-catenin signaling mediates tumor-immune avoidance Stefani Spranger, Thomas F. Gajewski K4 Intracellular tumor antigens as a source of targets of antibody-based immunotherapy of melanoma Yangyang Wang, Soldano Ferrone Combination therapies K5 Harnessing radiotherapy to improve responses to immunotherapy in cancer Claire Vanpouille-Box, Erik Wennerberg, Karsten A. Pilones, Silvia C. Formenti, Sandra Demaria K6 Creating a T cell-inflamed tumor microenvironment overcomes resistance to checkpoint blockade Haidong Tang, Yang Wang, Yang-Xin Fu K7 Biomarkers for treatment decisions? Reinhard Dummer K8 Combining oncolytic therapies in the era of checkpoint inhibitors Igor Puzanov K9 Immune checkpoint blockade for melanoma: should we combine or sequence ipilimumab and PD-1 antibody therapy? Michael A. Postow News in immunotherapy K10 An update on adjuvant and neoadjuvant therapy for melanom Ahmad Tarhini K11 Targeting multiple inhibitory receptors in melanoma Joe-Marc Chauvin, Ornella Pagliano, Julien Fourcade, Zhaojun Sun, Hong Wang, Cindy Sanders, John M. Kirkwood, Tseng-hui Timothy Chen, Mark Maurer, Alan J. Korman, Hassane M. Zarour K12 Improving adoptive immune therapy using genetically engineered T cells David F. Stroncek Tumor microenvironment and biomarkers K13 Myeloid cells and tumor exosomes: a crosstalk for assessing immunosuppression? Veronica Huber, Licia Rivoltini K14 Update on the SITC biomarker taskforce: progress and challenges Magdalena Thurin World-wide immunoscore task force: an update K15 The immunoscore in colorectal cancer highlights the importance of digital scoring systems in surgical pathology Tilman Rau, Alessandro Lugli K16 The immunoscore: toward an integrated immunomonitoring from the diagnosis to the follow up of cancer’s patients Franck Pagès Economic sustainability of melanoma treatments: regulatory, health technology assessment and market access issues K17 Nivolumab, the regulatory experience in immunotherapy Jorge Camarero, Arantxa Sancho K18 Evidence to optimize access for immunotherapies Claudio Jommi ORAL PRESENTATIONS Molecular and immuno-advances O1 Ipilimumab treatment results in CD4 T cell activation that is concomitant with a reduction in Tregs and MDSCs Yago Pico de Coaña, Maria Wolodarski, Yuya Yoshimoto, Giusy Gentilcore, Isabel Poschke, Giuseppe V. Masucci, Johan Hansson, Rolf Kiessling O2 Evaluation of prognostic and therapeutic potential of COX-2 and PD-L1 in primary and metastatic melanoma Giosuè Scognamiglio, Francesco Sabbatino, Federica Zito Marino, Anna Maria Anniciello, Monica Cantile, Margherita Cerrone, Stefania Scala, Crescenzo D’alterio, Angela Ianaro, Giuseppe Cirino, Paolo Antonio Ascierto, Giuseppina Liguori, Gerardo Botti O3 Vemurafenib in patients with BRAFV600 mutation–positive metastatic melanoma: final overall survival results of the BRIM-3 study Paul B. Chapman, Caroline Robert, James Larkin, John B. Haanen, Antoni Ribas, David Hogg, Omid Hamid, Paolo Antonio Ascierto, Alessandro Testori, Paul Lorigan, Reinhard Dummer, Jeffrey A. Sosman, Keith T. Flaherty, Huibin Yue, Shelley Coleman, Ivor Caro, Axel Hauschild, Grant A. McArthur O4 Updated survival, response and safety data in a phase 1 dose-finding study (CA209-004) of concurrent nivolumab (NIVO) and ipilimumab (IPI) in advanced melanoma Mario Sznol, Margaret K. Callahan, Harriet Kluger, Michael A. Postow, RuthAnn Gordan, Neil H. Segal, Naiyer A. Rizvi, Alexander Lesokhin, Michael B. Atkins, John M. Kirkwood, Matthew M. Burke, Amanda Ralabate, Angel Rivera, Stephanie A. Kronenberg, Blessing Agunwamba, Mary Ruisi, Christine Horak, Joel Jiang, Jedd Wolchok Combination therapies O5 Efficacy and correlative biomarker analysis of the coBRIM study comparing cobimetinib (COBI) + vemurafenib (VEM) vs placebo (PBO) + VEM in advanced BRAF-mutated melanoma patients (pts) Paolo A. Ascierto, Grant A. McArthur, James Larkin, Gabriella Liszkay, Michele Maio, Mario Mandalà, Lev Demidov, Daniil Stoyakovskiy, Luc Thomas, Luis de la Cruz-Merino, Victoria Atkinson, Caroline Dutriaux, Claus Garbe, Matthew Wongchenko, Ilsung Chang, Daniel O. Koralek, Isabelle Rooney, Yibing Yan, Antoni Ribas, Brigitte Dréno O6 Preliminary clinical safety, tolerability and activity results from a Phase Ib study of atezolizumab (anti-PDL1) combined with vemurafenib in BRAFV600-mutant metastatic melanoma Ryan Sullivan, Omid Hamid, Manish Patel, Stephen Hodi, Rodabe Amaria, Peter Boasberg, Jeffrey Wallin, Xian He, Edward Cha, Nicole Richie, Marcus Ballinger, Patrick Hwu O7 Preliminary safety and efficacy data from a phase 1/2 study of epacadostat (INCB024360) in combination with pembrolizumab in patients with advanced/metastatic melanoma Thomas F. Gajewski, Omid Hamid, David C. Smith, Todd M. Bauer, Jeffrey S. Wasser, Jason J. Luke, Ani S. Balmanoukian, David R. Kaufman, Yufan Zhao, Janet Maleski, Lance Leopold, Tara C. Gangadhar O8 Primary analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma Reinhard Dummer, Georgina V. Long, Antoni Ribas, Igor Puzanov, Olivier Michielin, Ari VanderWalde, Robert H.I. Andtbacka, Jonathan Cebon, Eugenio Fernandez, Josep Malvehy, Anthony J. Olszanski, Thomas F. Gajewski, John M. Kirkwood, Christine Gause, Lisa Chen, David R. Kaufman, Jeffrey Chou, F. Stephen Hodi News in immunotherapy O9 Two-year survival and safety update in patients (pts) with treatment-naïve advanced melanoma (MEL) receiving nivolumab (NIVO) or dacarbazine (DTIC) in CheckMate 066 Victoria Atkinson, Paolo A. Ascierto, Georgina V. Long, Benjamin Brady, Caroline Dutriaux, Michele Maio, Laurent Mortier, Jessica C. Hassel, Piotr Rutkowski, Catriona McNeil, Ewa Kalinka-Warzocha, Celeste Lebbé, Lars Ny, Matias Chacon, Paola Queirolo, Carmen Loquai, Parneet Cheema, Alfonso Berrocal, Karmele Mujika Eizmendi, Luis De La Cruz-Merino, Gil Bar-Sela, Christine Horak, Joel Jiang, Helene Hardy, Caroline Robert O10 Efficacy and safety of nivolumab (NIVO) in patients (pts) with advanced melanoma (MEL) who were treated beyond progression in CheckMate 066/067 Georgina V. Long, Jeffrey S. Weber, James Larkin, Victoria Atkinson, Jean-Jacques Grob, Reinhard Dummer, Caroline Robert, Ivan Marquez-Rodas, Catriona McNeil, Henrik Schmidt, Karen Briscoe, Jean-François Baurain, F. Stephen Hodi, Jedd D. Wolchok Tumor microenvironment and biomarkers O11 New biomarkers for response/resistance to BRAF inhibitor therapy in metastatic melanoma Rosamaria Pinto, Simona De Summa, Vito Michele Garrisi, Sabino Strippoli, Amalia Azzariti, Gabriella Guida, Michele Guida, Stefania Tommasi O12 Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma and response to ipilimumab Nicolas Jacquelot, David Enot, Caroline Flament, Jonathan M. Pitt, Nadège Vimond, Carolin Blattner, Takahiro Yamazaki, Maria-Paula Roberti, Marie Vetizou, Romain Daillere, Vichnou Poirier-Colame, Michaëla Semeraro, Anne Caignard, Craig L Slingluff Jr, Federica Sallusto, Sylvie Rusakiewicz, Benjamin Weide, Aurélien Marabelle, Holbrook Kohrt, Stéphane Dalle, Andréa Cavalcanti, Guido Kroemer, Anna Maria Di Giacomo, Michaele Maio, Phillip Wong, Jianda Yuan, Jedd Wolchok, Viktor Umansky, Alexander Eggermont, Laurence Zitvogel O13 Serum levels of PD1- and CD28-positive exosomes before Ipilimumab correlate with therapeutic response in metastatic melanoma patients Passarelli Anna, Tucci Marco, Stucci Stefania, Mannavola Francesco, Capone Mariaelena, Madonna Gabriele, Ascierto Paolo Antonio, Silvestris Franco O14 Immunological prognostic factors in stage III melanomas María Paula Roberti, Nicolas Jacquelot, David P Enot, Sylvie Rusakiewicz, Michaela Semeraro, Sarah Jégou, Camila Flores, Lieping Chen, Byoung S. Kwon, Ana Carrizossa Anderson, Caroline Robert, Christophe Borg, Benjamin Weide, François Aubin, Stéphane Dalle, Michele Maio, Jedd D. Wolchok, Holbrook Kohrt, Maha Ayyoub, Guido Kroemer, Aurélien Marabelle, Andréa Cavalcanti, Alexander Eggermont, Laurence Zitvogel POSTER PRESENTATIONS Molecular and immuno-advances P1 Human melanoma cells resistant to B-RAF and MEK inhibition exhibit mesenchymal-like features Anna Lisa De Presbiteris, Fabiola Gilda Cordaro, Rosa Camerlingo, Federica Fratangelo, Nicola Mozzillo, Giuseppe Pirozzi, Eduardo J. Patriarca, Paolo A. Ascierto, Emilia Caputo P2 Anti-proliferative and pro-apoptotic effect of ABT888 on melanoma cell lines and its potential role in the treatment of melanoma resistant to B-RAF inhibitors Federica Fratangelo, Rosa Camerlingo, Emilia Caputo, Maria Letizia Motti, Rosaria Falcone, Roberta Miceli, Mariaelena Capone, Gabriele Madonna, Domenico Mallardo, Maria Vincenza Carriero, Giuseppe Pirozzi and Paolo Antonio Ascierto P3 Involvement of the L-cysteine/CSE/H2S pathway in human melanoma progression Elisabetta Panza, Paola De Cicco, Chiara Armogida, Giuseppe Ercolano, Rosa Camerlingo, Giuseppe Pirozzi, Giosuè Scognamiglio, Gerardo Botti, Giuseppe Cirino, Angela Ianaro P4 Cancer stem cell antigen revealing pattern of antibody variable region genes were defined by immunoglobulin repertoire analysis in patients with malignant melanoma Beatrix Kotlan, Gabriella Liszkay, Miri Blank, Timea Balatoni, Judit Olasz, Emil Farkas, Andras Szollar, Akos Savolt, Maria Godeny, Orsolya Csuka, Szabolcs Horvath, Klara Eles, Yehuda Shoenfeld and Miklos Kasler P5 Upregulation of Neuregulin-1 expression is a hallmark of adaptive response to BRAF/MEK inhibitors in melanoma Debora Malpicci, Luigi Fattore, Susan Costantini, Francesca Capone, Paolo Antonio Ascierto, Rita Mancini, Gennaro Ciliberto P6 HuR positively regulates migration of HTB63 melanoma cells Farnaz Moradi, Pontus Berglund, Karin Leandersson, Rickard Linnskog, Tommy Andersson, Chandra Prakash Prasad P7 Prolyl 4- (C-P4H) hydroxylases have opposing effects in malignant melanoma: implication in prognosis and therapy Cristiana Lo Nigro, Laura Lattanzio, Hexiao Wang, Charlotte Proby, Nelofer Syed, Marcella Occelli, Carolina Cauchi, Marco Merlano, Catherine Harwood, Alastair Thompson, Tim Crook P8 Urokinase receptor antagonists: novel agents for the treatment of melanoma Maria Letizia Motti, Katia Bifulco, Vincenzo Ingangi, Michele Minopoli, Concetta Ragone, Federica Fratangelo, Antonello Pessi, Gennaro Ciliberto, Paolo Antonio Ascierto, Maria Vincenza Carriero P9 Exosomes released by melanoma cell lines enhance chemotaxis of primary tumor cells Francesco Mannavola, Stella D’Oronzo, Claudia Felici, Marco Tucci, Antonio Doronzo, Franco Silvestris P10 New insights in mitochondrial metabolic reprogramming in melanoma Anna Ferretta, Gabriella Guida, Stefania Guida, Imma Maida, Tiziana Cocco, Sabino Strippoli, Stefania Tommasi, Amalia Azzariti, Michele Guida P11 Lenalidomide restrains the proliferation in melanoma cells through a negative regulation of their cell cycle Stella D’Oronzo, Anna Passarelli, Claudia Felici, Marco Tucci, Davide Quaresmini, Franco Silvestris Combination therapies P12 Chemoimmunotherapy elicits polyfunctional anti-tumor CD8 + T cells depending on the activation of an AKT pathway sustained by ICOS Ornella Franzese, Belinda Palermo, Cosmo Di Donna, Isabella Sperduti, MariaLaura Foddai, Helena Stabile, Angela Gismondi, Angela Santoni, Paola Nisticò P13 Favourable toxicity profile of combined BRAF and MEK inhibitors in metastatic melanoma patients Andrea P. Sponghini, Francesca Platini, Elena Marra, David Rondonotti, Oscar Alabiso, Maria T. Fierro, Paola Savoia, Florian Stratica, Pietro Quaglino P14 Electrothermal bipolar vessel sealing system dissection reduces seroma output or time to drain removal following axillary and ilio-inguinal node dissection in melanoma patients: a pilot study Di Monta Gianluca, Caracò Corrado, Di Marzo Massimiliano, Marone Ugo, Di Cecilia Maria Luisa, Mozzillo Nicola News in immunotherapy P15 Clinical and immunological response to ipilimumab in a metastatic melanoma patient with HIV infection Francesco Sabbatino, Celeste Fusciello1, Antonio Marra, Rosario Guarrasi, Carlo Baldi, Rosa Russo, Di Giulio Giovanni, Vincenzo Faiola, Pio Zeppa, Stefano Pepe P16 Immunotherapy and hypophysitis: a case report Elisabetta Gambale, Consiglia Carella, Alessandra Di Paolo, Michele De Tursi Tumor microenvironment and biomarkers P17 New immuno- histochemical markers for the differential diagnosis of atypical melanocytic lesions with uncertain malignant potential Laura Marra, Giosuè Scognamiglio, Monica Cantile, Margherita Cerrone, Fara De Murtas, Valeria Sorrentino, Anna Maria Anniciello, Gerardo Botti P18 Utility of simultaneous measurement of three serum tumor markers in melanoma patients Angela Sandru, Silviu Voinea, Eugenia Panaitescu, Madalina Bolovan, Adina Stanciu, Sabin Cinca P19 The significance of various cut-off levels of melanoma inhibitory activity in evaluation of cutaneous melanoma patients Angela Sandru, Silviu Voinea, Eugenia Panaitescu, Madalina Bolovan, Adina Stanciu, Sabin Cinca P20 The long noncoding RNA HOTAIR is associated to metastatic progression of melanoma and it can be identified in the blood of patients with advanced disease Chiara Botti, Giosuè Scognamiglio, Laura Marra, Gabriella Aquino, Rosaria Falcone, Annamaria Anniciello, Paolo Antonio Ascierto, Gerardo Botti, Monica Cantile Other P21 The effect of Sentinel Lymph Node Biopsy in melanoma mortality: timing of dissection Cristina Fortes, Simona Mastroeni, Alessio Caggiati, Francesca Passarelli, Alba Zappalà, Maria Capuano, Riccardo Bono, Maurizio Nudo, Claudia Marino, Paola Michelozzi P22 Epidemiological survey on related psychopathology in melanoma Valeria De Biasio, Vincenzo C. Battarra IMMUNOTHERAPY BRIDGE KEYNOTE SPEAKER PRESENTATIONS Immunotherapy beyond melanoma K19 Predictor of response to radiation and immunotherapy Silvia Formenti K20 Response and resistance to PD-1 pathway blockade: clues from the tumor microenvironment Maria Libera Ascierto, Tracee L. McMiller, Alan E. Berger, Ludmila Danilova, Robert A. Anders, George J. Netto, Haiying Xu, Theresa S. Pritchard, Jinshui Fan, Chris Cheadle, Leslie Cope, Charles G. Drake, Drew M. Pardoll, Janis M. Taube and Suzanne L. Topalian K21 Combination immunotherapy with autologous stem cell transplantation, protein immunization, and PBMC reinfusion in myeloma patients Sacha Gnjatic, Sarah Nataraj, Naoko Imai, Adeeb Rahman, Achim A. Jungbluth, Linda Pan, Ralph Venhaus, Andrew Park, Frédéric F. Lehmann, Nikoletta Lendvai, Adam D. Cohen, and Hearn J. Cho K22 Anti-cancer immunity despite T cell “exhaustion” Speiser Daniel Immunotherapy in oncology (I-O): data from clinical trial K23 The Checkpoint Inhibitors for the Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) Vera Hirsh
- Published
- 2016
10. Phase Ib Trial of Phenformin in Patients with V600-mutated Melanoma Receiving Dabrafenib and Trametinib
- Author
-
Chapman, Paul B., primary, Klang, Mark, additional, Postow, Michael A., additional, Shoushtari, Alexander Noor, additional, Sullivan, Ryan J., additional, Wolchok, Jedd D., additional, Merghoub, Taha, additional, Budhu, Sadna, additional, Wong, Phillip, additional, Callahan, Margaret K., additional, Zheng, Bin, additional, and Zippin, Jonathan, additional
- Published
- 2023
- Full Text
- View/download PDF
11. Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade
- Author
-
Bello, Danielle M., Panageas, Katherine S., Hollmann, Travis, Shoushtari, Alexander N., Momtaz, Parisa, Chapman, Paul B., Postow, Michael A., Callahan, Margaret K., Wolchok, Jedd D., Brady, Mary S., Coit, Daniel G., and Ariyan, Charlotte E.
- Published
- 2020
- Full Text
- View/download PDF
12. Long-term outcome in BRAF V600E melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression
- Author
-
Puzanov, Igor, Amaravadi, Ravi K, McArthur, Grant A, Flaherty, Keith T, Chapman, Paul B, Sosman, Jeffrey A, Ribas, Antoni, Shackleton, Mark, Hwu, Patrick, Chmielowski, Bartosz, Nolop, Keith B, Lin, Paul S, and Kim, Kevin B
- Subjects
Cancer ,Brain Disorders ,Clinical Trials and Supportive Activities ,Clinical Research ,Adult ,Aged ,Aged ,80 and over ,Disease Progression ,Disease-Free Survival ,Dose-Response Relationship ,Drug ,Female ,Humans ,Indoles ,Male ,Melanoma ,Middle Aged ,Proto-Oncogene Proteins B-raf ,Skin Neoplasms ,Sulfonamides ,Survival Rate ,Vemurafenib ,Young Adult ,BRAF inhibitor ,Metastatic melanoma ,Oncology and Carcinogenesis ,Public Health and Health Services ,Oncology & Carcinogenesis - Abstract
IntroductionVemurafenib induces tumour regression in most patients with BRAF(V600E)-mutant melanoma; eventually, most experience progressive disease (PD). Long-term follow-up of patients with BRAF(V600E) melanoma treated in the phase 1 vemurafenib trial is reported.MethodsPatients received vemurafenib 240-1120 mg (dose escalation cohort) or 960 mg (extension cohort) orally twice daily. Clinical response was evaluated every 8 weeks by Response Evaluation Criteria In Solid Tumors (RECIST). Patients with PD amenable to local therapy (surgery or radiotherapy) were allowed to continue vemurafenib after progression. Overall survival (OS) from time of treatment initiation and from PD was estimated. Sites of PD were recorded.ResultsForty-eight patients (escalation cohort, n = 16; extension cohort, n = 32) received therapeutic doses of vemurafenib (⩾ 240 mg twice daily). Forty-four patients had PD by the time of this analysis and four remained progression free (follow-up time, 1.2-56.1 months). Median OS was 14 months (range, 1.2-56.1); 3- and 4-year melanoma-specific survival rate in the extension cohort was 26% and 19%, respectively. Median OS was 26.0 months (range, 7.7-56.1) among 20 patients who continued vemurafenib after local therapy. Median treatment duration beyond initial PD was 3.8 months (range, 1.1-26.6). In the extension cohort, six and five patients were alive after 3 and 4 years, respectively, on vemurafenib monotherapy.ConclusionsSome patients with melanoma achieved long-term survival with vemurafenib monotherapy. Continuation of vemurafenib after PD might be beneficial in some patients because remaining disease might continue to respond to BRAF inhibition.
- Published
- 2015
13. Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition
- Author
-
Carvajal, Richard D, Lawrence, Donald P, Weber, Jeffrey S, Gajewski, Thomas F, Gonzalez, Rene, Lutzky, Jose, O'Day, Steven J, Hamid, Omid, Wolchok, Jedd D, Chapman, Paul B, Sullivan, Ryan J, Teitcher, Jerrold B, Ramaiya, Nikhil, Giobbie-Hurder, Anita, Antonescu, Cristina R, Heinrich, Michael C, Bastian, Boris C, Corless, Christopher L, Fletcher, Jonathan A, and Hodi, F Stephen
- Subjects
Clinical Research ,Clinical Trials and Supportive Activities ,Cancer ,Rare Diseases ,Adult ,Aged ,Aged ,80 and over ,Antineoplastic Agents ,Brain Neoplasms ,Disease Progression ,Drug Resistance ,Neoplasm ,Female ,Humans ,Male ,Melanoma ,Middle Aged ,Proto-Oncogene Proteins c-kit ,Pyrimidines ,Skin Neoplasms ,Treatment Outcome ,Oncology and Carcinogenesis ,Oncology & Carcinogenesis - Abstract
PurposeAlthough durable responses can be achieved with tyrosine kinase inhibitors such as imatinib in melanomas harboring KIT mutations, the efficacy of alternative inhibitors after progression to imatinib and the activity of these agents on brain metastases are unknown.Experimental designWe conducted a phase II study of nilotinib 400 mg twice a day in two cohorts of patients with melanomas harboring KIT mutations or amplification: (A) those refractory or intolerant to a prior KIT inhibitor; and (B) those with brain metastases. The primary endpoint was 4-month disease control rate. Secondary endpoints included response rate, time-to-progression (TTP), and overall survival (OS). A Simon two-stage and a single-stage design was planned to assess for the primary endpoint in cohorts A and B, respectively.ResultsTwenty patients were enrolled and 19 treated (11 in cohort A; 8 in cohort B). Three patients on cohort A [27%; 95% confidence interval (CI), 8%-56%] and 1 on cohort B (12.5%; 90% CI, 0.6%-47%) achieved the primary endpoint. Two partial responses were observed in cohort A (18.2%; 90% CI, 3%-47%); none were observed in cohort B. The median TTP and OS was 3.3 (90% CI, 2.1-3.9 months) and 9.1 months (90% CI, 4.3-14.2 months), respectively, in all treated patients.ConclusionsNilotinib may achieve disease control in patients with melanoma harboring KIT alterations and whose disease progressed after imatinib therapy. The efficacy of this agent in KIT-altered melanoma with brain metastasis is limited.
- Published
- 2015
14. Loss of NF1 in Cutaneous Melanoma Is Associated with RAS Activation and MEK Dependence
- Author
-
Nissan, Moriah H, Pratilas, Christine A, Jones, Alexis M, Ramirez, Ricardo, Won, Helen, Liu, Cailian, Tiwari, Shakuntala, Kong, Li, Hanrahan, Aphrothiti J, Yao, Zhan, Merghoub, Taha, Ribas, Antoni, Chapman, Paul B, Yaeger, Rona, Taylor, Barry S, Schultz, Nikolaus, Berger, Michael F, Rosen, Neal, and Solit, David B
- Subjects
Neurosciences ,Cancer ,Cell Line ,Tumor ,Cell Proliferation ,GTP Phosphohydrolases ,Genes ,Neurofibromatosis 1 ,Genes ,ras ,Humans ,MAP Kinase Kinase Kinases ,MAP Kinase Signaling System ,Melanoma ,Membrane Proteins ,Neurofibromin 1 ,Phosphorylation ,Proto-Oncogene Proteins B-raf ,Skin Neoplasms ,Oncology and Carcinogenesis ,Oncology & Carcinogenesis - Abstract
Melanoma is a disease characterized by lesions that activate ERK. Although 70% of cutaneous melanomas harbor activating mutations in the BRAF and NRAS genes, the alterations that drive tumor progression in the remaining 30% are largely undefined. Vemurafenib, a selective inhibitor of RAF kinases, has clinical utility restricted to BRAF-mutant tumors. MEK inhibitors, which have shown clinical activity in NRAS-mutant melanoma, may be effective in other ERK pathway-dependent settings. Here, we investigated a panel of melanoma cell lines wild type for BRAF and NRAS to determine the genetic alteration driving their transformation and their dependence on ERK signaling in order to elucidate a candidate set for MEK inhibitor treatment. A cohort of the BRAF/RAS wild type cell lines with high levels of RAS-GTP had loss of NF1, a RAS GTPase activating protein. In these cell lines, the MEK inhibitor PD0325901 inhibited ERK phosphorylation, but also relieved feedback inhibition of RAS, resulting in induction of pMEK and a rapid rebound in ERK signaling. In contrast, the MEK inhibitor trametinib impaired the adaptive response of cells to ERK inhibition, leading to sustained suppression of ERK signaling and significant antitumor effects. Notably, alterations in NF1 frequently co-occurred with RAS and BRAF alterations in melanoma. In the setting of BRAF(V600E), NF1 loss abrogated negative feedback on RAS activation, resulting in elevated activation of RAS-GTP and resistance to RAF, but not MEK, inhibitors. We conclude that loss of NF1 is common in cutaneous melanoma and is associated with RAS activation, MEK-dependence, and resistance to RAF inhibition.
- Published
- 2014
15. Safety and efficacy of vemurafenib in BRAF V600E and BRAF V600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
- Author
-
McArthur, Grant A, Chapman, Paul B, Robert, Caroline, Larkin, James, Haanen, John B, Dummer, Reinhard, Ribas, Antoni, Hogg, David, Hamid, Omid, Ascierto, Paolo A, Garbe, Claus, Testori, Alessandro, Maio, Michele, Lorigan, Paul, Lebbé, Celeste, Jouary, Thomas, Schadendorf, Dirk, O'Day, Stephen J, Kirkwood, John M, Eggermont, Alexander M, Dréno, Brigitte, Sosman, Jeffrey A, Flaherty, Keith T, Yin, Ming, Caro, Ivor, Cheng, Suzanne, Trunzer, Kerstin, and Hauschild, Axel
- Subjects
Genetics ,Cancer ,Clinical Trials and Supportive Activities ,Clinical Research ,Prevention ,Good Health and Well Being ,Adult ,Aged ,Dacarbazine ,Disease-Free Survival ,Female ,Follow-Up Studies ,Humans ,Indoles ,Male ,Melanoma ,Middle Aged ,Mutation ,Protein Kinase Inhibitors ,Proto-Oncogene Proteins B-raf ,Sulfonamides ,Vemurafenib ,Oncology and Carcinogenesis ,Oncology & Carcinogenesis - Abstract
BackgroundIn the BRIM-3 trial, vemurafenib was associated with risk reduction versus dacarbazine of both death and progression in patients with advanced BRAF(V600) mutation-positive melanoma. We present an extended follow-up analysis of the total population and in the BRAF(V600E) and BRAF(V600K) mutation subgroups.MethodsPatients older than 18 years, with treatment-naive metastatic melanoma and whose tumour tissue was positive for BRAF(V600) mutations were eligible. Patients also had to have a life expectancy of at least 3 months, an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and adequate haematological, hepatic, and renal function. Patients were randomly assigned by interactive voice recognition system to receive either vemurafenib (960 mg orally twice daily) or dacarbazine (1000 mg/m(2) of body surface area intravenously every 3 weeks). Coprimary endpoints were overall survival and progression-free survival, analysed in the intention-to-treat population (n=675), with data censored at crossover. A sensitivity analysis was done. This trial is registered with ClinicalTrials.gov, NCT01006980.Findings675 eligible patients were enrolled from 104 centres in 12 countries between Jan 4, 2010, and Dec 16, 2010. 337 patients were randomly assigned to receive vemurafenib and 338 to receive dacarbazine. Median follow-up was 12·5 months (IQR 7·7-16·0) on vemurafenib and 9·5 months (3·1-14·7) on dacarbazine. 83 (25%) of the 338 patients initially randomly assigned to dacarbazine crossed over from dacarbazine to vemurafenib. Median overall survival was significantly longer in the vemurafenib group than in the dacarbazine group (13·6 months [95% CI 12·0-15·2] vs 9·7 months [7·9-12·8]; hazard ratio [HR] 0·70 [95% CI 0·57-0·87]; p=0·0008), as was median progression-free survival (6·9 months [95% CI 6·1-7·0] vs 1·6 months [1·6-2·1]; HR 0·38 [95% CI 0·32-0·46]; p
- Published
- 2014
16. A Single-Arm, Open-Label, Expanded Access Study of Vemurafenib in Patients With Metastatic Melanoma in the United States
- Author
-
Flaherty, Lawrence, Hamid, Omid, Linette, Gerald, Schuchter, Lynn, Hallmeyer, Sigrun, Gonzalez, Rene, Cowey, C Lance, Pavlick, Anna, Kudrik, Fred, Curti, Brendan, Lawson, David, Chapman, Paul B, Margolin, Kim, Ribas, Antoni, McDermott, David, Flaherty, Keith, Cranmer, Lee, Hodi, F Stephen, Day, Bann-Mo, Linke, Rolf, and Hainsworth, John
- Subjects
Cancer ,Clinical Trials and Supportive Activities ,Patient Safety ,Neurosciences ,Clinical Research ,Female ,Humans ,Indoles ,Male ,Melanoma ,Middle Aged ,Neoplasm Metastasis ,Skin Neoplasms ,Sulfonamides ,United States ,Vemurafenib ,Melanoma/drug therapy ,melanoma/genetics ,BRAF protein ,human ,neoplasm metastasis/drug therapy ,brain neoplasms/secondary ,brain neoplasms/drug therapy ,vemurafenib/therapeutic use ,vemurafenib/adverse effects ,clinical trial ,humans ,Oncology and Carcinogenesis ,Oncology & Carcinogenesis - Abstract
PurposeThis open-label, multicenter study was designed to allow access to vemurafenib for patients with metastatic melanoma, bridging the time between end of enrollment in the phase III registration trial (December 2010) and commercial availability following US Food and Drug Administration approval of vemurafenib for the treatment of unresectable or metastatic BRAF-mutated melanoma (August 2011).Patients and methodsEligible patients had metastatic melanoma with a BRAF mutation (detected by the cobas 4800 BRAF V600 Mutation Test). Unlike previous vemurafenib trials, patients with poor performance status (PS) and treated brain metastases were permitted. Enrolled patients received oral vemurafenib 960 mg twice daily.ResultsOf 374 patients enrolled at 29 US sites (December 2010 to October 2011), 371 patients received vemurafenib and were followed up for a median of 2.8 months (the study had a prespecified end upon vemurafenib approval and commercial availability). At baseline, most patients (75%) had stage M1c disease, and 19% had an Eastern Cooperative Oncology Group PS of 2 or 3; 72% of patients had received prior systemic therapy for metastatic melanoma, 27% received prior ipilimumab, and 29% radiotherapy for prior brain metastases. Because reassessment data to confirm response were not available for most patients, point estimates of objective response rate (ORR) are reported. Among 241 efficacy-evaluable patients, the ORR was 54% (median time to response, 1.9 months). The ORR in non-central nervous system sites in patients with previously treated brain metastases (n = 68) was 53%. The ORR in prior ipilimumab-treated patients (n = 68) was 52%. For patients with PS of 0 or 1 (n = 210) and 2 or 3 (n = 31), the ORRs were 55%, and 42%, respectively. The safety profile observed was consistent with that reported in previous studies. The number of patients with grade 3 or 4 treatment-related adverse events was higher in patients with PS 2 or 3 than in those with PS 0 or 1 (10% vs. 5%, respectively). Adverse events requiring a dose reduction (at least 1 level) occurred in 11% of patients, and 9 patients (2%) experienced events leading to vemurafenib withdrawal, including 2 with repeated QT interval prolongation.DiscussionThis study confirmed the established rapid and high tumor response rate achievable with vemurafenib in BRAF mutation-positive metastatic melanoma. Several groups not included in previous studies, including patients with previously treated brain metastases, Eastern Cooperative Oncology Group PS 2 to 3, or previous ipilimumab treatment had benefitted from vemurafenib similar to the overall population. No new safety signals were detected.
- Published
- 2014
17. Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218)
- Author
-
Hodi, F. Stephen, Chapman, Paul B., Sznol, Mario, Lao, Christopher D., Gonzalez, Rene, Smylie, Michael, Daniels, Gregory A., Thompson, John A., Kudchadkar, Ragini, Sharfman, William, Atkins, Michael, Spigel, David R., Pavlick, Anna, Monzon, Jose, Kim, Kevin B., Ernst, Scott, Khushalani, Nikhil I., van Dijck, Wim, Lobo, Maurice, and Hogg, David
- Published
- 2021
- Full Text
- View/download PDF
18. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
- Author
-
Straussman, Ravid, Morikawa, Teppei, Shee, Kevin, Barzily-Rokni, Michal, Qian, Zhi Rong, Du, Jinyan, Davis, Ashli, Mongare, Margaret M, Gould, Joshua, Frederick, Dennie T, Cooper, Zachary A, Chapman, Paul B, Solit, David B, Ribas, Antoni, Lo, Roger S, Flaherty, Keith T, Ogino, Shuji, Wargo, Jennifer A, and Golub, Todd R
- Subjects
Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Cancer ,Antineoplastic Agents ,Antineoplastic Combined Chemotherapy Protocols ,Cell Line ,Tumor ,Coculture Techniques ,Drug Resistance ,Neoplasm ,Hepatocyte Growth Factor ,Humans ,Indoles ,Melanoma ,Molecular Targeted Therapy ,Mutation ,Phosphatidylinositol 3-Kinases ,Prognosis ,Protein Kinase Inhibitors ,Proteomics ,Proto-Oncogene Proteins B-raf ,Proto-Oncogene Proteins c-met ,Signal Transduction ,Stromal Cells ,Sulfonamides ,Tumor Microenvironment ,Vemurafenib ,General Science & Technology - Abstract
Drug resistance presents a challenge to the treatment of cancer patients. Many studies have focused on cell-autonomous mechanisms of drug resistance. By contrast, we proposed that the tumour micro-environment confers innate resistance to therapy. Here we developed a co-culture system to systematically assay the ability of 23 stromal cell types to influence the innate resistance of 45 cancer cell lines to 35 anticancer drugs. We found that stroma-mediated resistance is common, particularly to targeted agents. We characterized further the stroma-mediated resistance of BRAF-mutant melanoma to RAF inhibitors because most patients with this type of cancer show some degree of innate resistance. Proteomic analysis showed that stromal cell secretion of hepatocyte growth factor (HGF) resulted in activation of the HGF receptor MET, reactivation of the mitogen-activated protein kinase (MAPK) and phosphatidylinositol-3-OH kinase (PI(3)K)-AKT signalling pathways, and immediate resistance to RAF inhibition. Immunohistochemistry experiments confirmed stromal cell expression of HGF in patients with BRAF-mutant melanoma and showed a significant correlation between HGF expression by stromal cells and innate resistance to RAF inhibitor treatment. Dual inhibition of RAF and either HGF or MET resulted in reversal of drug resistance, suggesting RAF plus HGF or MET inhibitory combination therapy as a potential therapeutic strategy for BRAF-mutant melanoma. A similar resistance mechanism was uncovered in a subset of BRAF-mutant colorectal and glioblastoma cell lines. More generally, this study indicates that the systematic dissection of interactions between tumours and their micro-environment can uncover important mechanisms underlying drug resistance.
- Published
- 2012
19. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
- Author
-
Poulikakos, Poulikos I, Persaud, Yogindra, Janakiraman, Manickam, Kong, Xiangju, Ng, Charles, Moriceau, Gatien, Shi, Hubing, Atefi, Mohammad, Titz, Bjoern, Gabay, May Tal, Salton, Maayan, Dahlman, Kimberly B, Tadi, Madhavi, Wargo, Jennifer A, Flaherty, Keith T, Kelley, Mark C, Misteli, Tom, Chapman, Paul B, Sosman, Jeffrey A, Graeber, Thomas G, Ribas, Antoni, Lo, Roger S, Rosen, Neal, and Solit, David B
- Subjects
Genetics ,Cancer ,Development of treatments and therapeutic interventions ,5.1 Pharmaceuticals ,Alternative Splicing ,Animals ,Cell Line ,Tumor ,Drug Resistance ,Neoplasm ,Exons ,Extracellular Signal-Regulated MAP Kinases ,Humans ,Indoles ,MAP Kinase Signaling System ,Melanoma ,Mice ,Mutant Proteins ,Protein Isoforms ,Protein Kinase Inhibitors ,Protein Multimerization ,Proto-Oncogene Proteins B-raf ,Sulfonamides ,Vemurafenib ,General Science & Technology - Abstract
Activated RAS promotes dimerization of members of the RAF kinase family. ATP-competitive RAF inhibitors activate ERK signalling by transactivating RAF dimers. In melanomas with mutant BRAF(V600E), levels of RAS activation are low and these drugs bind to BRAF(V600E) monomers and inhibit their activity. This tumour-specific inhibition of ERK signalling results in a broad therapeutic index and RAF inhibitors have remarkable clinical activity in patients with melanomas that harbour mutant BRAF(V600E). However, resistance invariably develops. Here, we identify a new resistance mechanism. We find that a subset of cells resistant to vemurafenib (PLX4032, RG7204) express a 61-kDa variant form of BRAF(V600E), p61BRAF(V600E), which lacks exons 4-8, a region that encompasses the RAS-binding domain. p61BRAF(V600E) shows enhanced dimerization in cells with low levels of RAS activation, as compared to full-length BRAF(V600E). In cells in which p61BRAF(V600E) is expressed endogenously or ectopically, ERK signalling is resistant to the RAF inhibitor. Moreover, a mutation that abolishes the dimerization of p61BRAF(V600E) restores its sensitivity to vemurafenib. Finally, we identified BRAF(V600E) splicing variants lacking the RAS-binding domain in the tumours of six of nineteen patients with acquired resistance to vemurafenib. These data support the model that inhibition of ERK signalling by RAF inhibitors is dependent on levels of RAS-GTP too low to support RAF dimerization and identify a novel mechanism of acquired resistance in patients: expression of splicing isoforms of BRAF(V600E) that dimerize in a RAS-independent manner.
- Published
- 2011
20. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
- Author
-
Bollag, Gideon, Hirth, Peter, Tsai, James, Zhang, Jiazhong, Ibrahim, Prabha N, Cho, Hanna, Spevak, Wayne, Zhang, Chao, Zhang, Ying, Habets, Gaston, Burton, Elizabeth A, Wong, Bernice, Tsang, Garson, West, Brian L, Powell, Ben, Shellooe, Rafe, Marimuthu, Adhirai, Nguyen, Hoa, Zhang, Kam YJ, Artis, Dean R, Schlessinger, Joseph, Su, Fei, Higgins, Brian, Iyer, Raman, D’Andrea, Kurt, Koehler, Astrid, Stumm, Michael, Lin, Paul S, Lee, Richard J, Grippo, Joseph, Puzanov, Igor, Kim, Kevin B, Ribas, Antoni, McArthur, Grant A, Sosman, Jeffrey A, Chapman, Paul B, Flaherty, Keith T, Xu, Xiaowei, Nathanson, Katherine L, and Nolop, Keith
- Subjects
Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Clinical Trials and Supportive Activities ,Clinical Research ,Cancer ,5.1 Pharmaceuticals ,Development of treatments and therapeutic interventions ,Alleles ,Animals ,Dogs ,Extracellular Signal-Regulated MAP Kinases ,Humans ,Indoles ,MAP Kinase Signaling System ,Macaca fascicularis ,Melanoma ,Models ,Molecular ,Mutant Proteins ,Mutation ,Neoplasm Metastasis ,Phosphorylation ,Positron-Emission Tomography ,Proto-Oncogene Proteins B-raf ,Rats ,Substrate Specificity ,Sulfonamides ,Vemurafenib ,Xenograft Model Antitumor Assays ,General Science & Technology - Abstract
B-RAF is the most frequently mutated protein kinase in human cancers. The finding that oncogenic mutations in BRAF are common in melanoma, followed by the demonstration that these tumours are dependent on the RAF/MEK/ERK pathway, offered hope that inhibition of B-RAF kinase activity could benefit melanoma patients. Herein, we describe the structure-guided discovery of PLX4032 (RG7204), a potent inhibitor of oncogenic B-RAF kinase activity. Preclinical experiments demonstrated that PLX4032 selectively blocked the RAF/MEK/ERK pathway in BRAF mutant cells and caused regression of BRAF mutant xenografts. Toxicology studies confirmed a wide safety margin consistent with the high degree of selectivity, enabling Phase 1 clinical trials using a crystalline formulation of PLX4032 (ref. 5). In a subset of melanoma patients, pathway inhibition was monitored in paired biopsy specimens collected before treatment initiation and following two weeks of treatment. This analysis revealed substantial inhibition of ERK phosphorylation, yet clinical evaluation did not show tumour regressions. At higher drug exposures afforded by a new amorphous drug formulation, greater than 80% inhibition of ERK phosphorylation in the tumours of patients correlated with clinical response. Indeed, the Phase 1 clinical data revealed a remarkably high 81% response rate in metastatic melanoma patients treated at an oral dose of 960 mg twice daily. These data demonstrate that BRAF-mutant melanomas are highly dependent on B-RAF kinase activity.
- Published
- 2010
21. Beyond the 5‐year milestone: Long‐term survivorship of melanoma patients treated off‐trial with anti‐PD ‐1
- Author
-
Loo, Kimberly, primary, Kalvin, Hannah L., additional, Panageas, Katherine S., additional, Callahan, Margaret K., additional, Chapman, Paul B., additional, Momtaz, Parisa, additional, Shoushtari, Alexander N., additional, Wolchok, Jedd D., additional, Postow, Michael A., additional, and Warner, Allison Betof, additional
- Published
- 2023
- Full Text
- View/download PDF
22. Data from Efficacy of Intermittent Combined RAF and MEK Inhibition in a Patient with Concurrent BRAF- and NRAS-Mutant Malignancies
- Author
-
Abdel-Wahab, Omar, primary, Klimek, Virginia M., primary, Gaskell, Alisa A., primary, Viale, Agnes, primary, Cheng, Donavan, primary, Kim, Eunhee, primary, Rampal, Raajit, primary, Bluth, Mark, primary, Harding, James J., primary, Callahan, Margaret K., primary, Merghoub, Taha, primary, Berger, Michael F., primary, Solit, David B., primary, Rosen, Neal, primary, Levine, Ross L., primary, and Chapman, Paul B., primary
- Published
- 2023
- Full Text
- View/download PDF
23. Supplementary Figure 1 from Efficacy of Intermittent Combined RAF and MEK Inhibition in a Patient with Concurrent BRAF- and NRAS-Mutant Malignancies
- Author
-
Abdel-Wahab, Omar, primary, Klimek, Virginia M., primary, Gaskell, Alisa A., primary, Viale, Agnes, primary, Cheng, Donavan, primary, Kim, Eunhee, primary, Rampal, Raajit, primary, Bluth, Mark, primary, Harding, James J., primary, Callahan, Margaret K., primary, Merghoub, Taha, primary, Berger, Michael F., primary, Solit, David B., primary, Rosen, Neal, primary, Levine, Ross L., primary, and Chapman, Paul B., primary
- Published
- 2023
- Full Text
- View/download PDF
24. Supplementary Figure 2 from Efficacy of Intermittent Combined RAF and MEK Inhibition in a Patient with Concurrent BRAF- and NRAS-Mutant Malignancies
- Author
-
Abdel-Wahab, Omar, primary, Klimek, Virginia M., primary, Gaskell, Alisa A., primary, Viale, Agnes, primary, Cheng, Donavan, primary, Kim, Eunhee, primary, Rampal, Raajit, primary, Bluth, Mark, primary, Harding, James J., primary, Callahan, Margaret K., primary, Merghoub, Taha, primary, Berger, Michael F., primary, Solit, David B., primary, Rosen, Neal, primary, Levine, Ross L., primary, and Chapman, Paul B., primary
- Published
- 2023
- Full Text
- View/download PDF
25. Supplementary Tables and Legend from Efficacy of Intermittent Combined RAF and MEK Inhibition in a Patient with Concurrent BRAF- and NRAS-Mutant Malignancies
- Author
-
Abdel-Wahab, Omar, primary, Klimek, Virginia M., primary, Gaskell, Alisa A., primary, Viale, Agnes, primary, Cheng, Donavan, primary, Kim, Eunhee, primary, Rampal, Raajit, primary, Bluth, Mark, primary, Harding, James J., primary, Callahan, Margaret K., primary, Merghoub, Taha, primary, Berger, Michael F., primary, Solit, David B., primary, Rosen, Neal, primary, Levine, Ross L., primary, and Chapman, Paul B., primary
- Published
- 2023
- Full Text
- View/download PDF
26. Supplementary Figure 3 from Efficacy of Intermittent Combined RAF and MEK Inhibition in a Patient with Concurrent BRAF- and NRAS-Mutant Malignancies
- Author
-
Abdel-Wahab, Omar, primary, Klimek, Virginia M., primary, Gaskell, Alisa A., primary, Viale, Agnes, primary, Cheng, Donavan, primary, Kim, Eunhee, primary, Rampal, Raajit, primary, Bluth, Mark, primary, Harding, James J., primary, Callahan, Margaret K., primary, Merghoub, Taha, primary, Berger, Michael F., primary, Solit, David B., primary, Rosen, Neal, primary, Levine, Ross L., primary, and Chapman, Paul B., primary
- Published
- 2023
- Full Text
- View/download PDF
27. Supplementary Figure 4 from Efficacy of Intermittent Combined RAF and MEK Inhibition in a Patient with Concurrent BRAF- and NRAS-Mutant Malignancies
- Author
-
Abdel-Wahab, Omar, primary, Klimek, Virginia M., primary, Gaskell, Alisa A., primary, Viale, Agnes, primary, Cheng, Donavan, primary, Kim, Eunhee, primary, Rampal, Raajit, primary, Bluth, Mark, primary, Harding, James J., primary, Callahan, Margaret K., primary, Merghoub, Taha, primary, Berger, Michael F., primary, Solit, David B., primary, Rosen, Neal, primary, Levine, Ross L., primary, and Chapman, Paul B., primary
- Published
- 2023
- Full Text
- View/download PDF
28. Figure S1 from Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas
- Author
-
Shoushtari, Alexander N., primary, Chatila, Walid K., primary, Arora, Arshi, primary, Sanchez-Vega, Francisco, primary, Kantheti, Havish S., primary, Rojas Zamalloa, Jorge A., primary, Krieger, Penina, primary, Callahan, Margaret K., primary, Betof Warner, Allison, primary, Postow, Michael A., primary, Momtaz, Parisa, primary, Nair, Suresh, primary, Ariyan, Charlotte E., primary, Barker, Christopher A., primary, Brady, Mary Susan, primary, Coit, Daniel G., primary, Rosen, Neal, primary, Chapman, Paul B., primary, Busam, Klaus J., primary, Solit, David B., primary, Panageas, Katherine S., primary, Wolchok, Jedd D., primary, and Schultz, Nikolaus, primary
- Published
- 2023
- Full Text
- View/download PDF
29. Supplementary Table S1 from Quantifying Treatment Benefit in Molecular Subgroups to Assess a Predictive Biomarker
- Author
-
Iasonos, Alexia, primary, Chapman, Paul B., primary, and Satagopan, Jaya M., primary
- Published
- 2023
- Full Text
- View/download PDF
30. Supplementary Figure 2 from Phase II Trial of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with BRAFV600E/K-Mutated Melanoma
- Author
-
Catalanotti, Federica, primary, Solit, David B., primary, Pulitzer, Melissa P., primary, Berger, Michael F., primary, Scott, Sasinya N., primary, Iyriboz, Tunc, primary, Lacouture, Mario E., primary, Panageas, Katherine S., primary, Wolchok, Jedd D., primary, Carvajal, Richard D., primary, Schwartz, Gary K., primary, Rosen, Neal, primary, and Chapman, Paul B., primary
- Published
- 2023
- Full Text
- View/download PDF
31. Table S1 from Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas
- Author
-
Shoushtari, Alexander N., primary, Chatila, Walid K., primary, Arora, Arshi, primary, Sanchez-Vega, Francisco, primary, Kantheti, Havish S., primary, Rojas Zamalloa, Jorge A., primary, Krieger, Penina, primary, Callahan, Margaret K., primary, Betof Warner, Allison, primary, Postow, Michael A., primary, Momtaz, Parisa, primary, Nair, Suresh, primary, Ariyan, Charlotte E., primary, Barker, Christopher A., primary, Brady, Mary Susan, primary, Coit, Daniel G., primary, Rosen, Neal, primary, Chapman, Paul B., primary, Busam, Klaus J., primary, Solit, David B., primary, Panageas, Katherine S., primary, Wolchok, Jedd D., primary, and Schultz, Nikolaus, primary
- Published
- 2023
- Full Text
- View/download PDF
32. Supplemental Methods from A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma
- Author
-
Postow, Michael A., primary, Knox, Susan J., primary, Goldman, Debra A., primary, Elhanati, Yuval, primary, Mavinkurve, Vikram, primary, Wong, Phillip, primary, Halpenny, Darragh, primary, Reddy, Sunil K., primary, Vado, Kenya, primary, McCabe, Danielle, primary, Ramirez, Kristen Aufiero, primary, Macri, Mary, primary, Schwarzenberger, Paul, primary, Ricciardi, Toni, primary, Ryan, Aileen, primary, Venhaus, Ralph, primary, Momtaz, Parisa, primary, Shoushtari, Alexander N., primary, Callahan, Margaret K., primary, Chapman, Paul B., primary, Wolchok, Jedd D., primary, Subrahmanyam, Priyanka B., primary, Maecker, Holden T., primary, Panageas, Katherine S., primary, and Barker, Christopher A., primary
- Published
- 2023
- Full Text
- View/download PDF
33. Supplemental Table 4 from A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma
- Author
-
Postow, Michael A., primary, Knox, Susan J., primary, Goldman, Debra A., primary, Elhanati, Yuval, primary, Mavinkurve, Vikram, primary, Wong, Phillip, primary, Halpenny, Darragh, primary, Reddy, Sunil K., primary, Vado, Kenya, primary, McCabe, Danielle, primary, Ramirez, Kristen Aufiero, primary, Macri, Mary, primary, Schwarzenberger, Paul, primary, Ricciardi, Toni, primary, Ryan, Aileen, primary, Venhaus, Ralph, primary, Momtaz, Parisa, primary, Shoushtari, Alexander N., primary, Callahan, Margaret K., primary, Chapman, Paul B., primary, Wolchok, Jedd D., primary, Subrahmanyam, Priyanka B., primary, Maecker, Holden T., primary, Panageas, Katherine S., primary, and Barker, Christopher A., primary
- Published
- 2023
- Full Text
- View/download PDF
34. Supplemental Figure 2 from A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma
- Author
-
Postow, Michael A., primary, Knox, Susan J., primary, Goldman, Debra A., primary, Elhanati, Yuval, primary, Mavinkurve, Vikram, primary, Wong, Phillip, primary, Halpenny, Darragh, primary, Reddy, Sunil K., primary, Vado, Kenya, primary, McCabe, Danielle, primary, Ramirez, Kristen Aufiero, primary, Macri, Mary, primary, Schwarzenberger, Paul, primary, Ricciardi, Toni, primary, Ryan, Aileen, primary, Venhaus, Ralph, primary, Momtaz, Parisa, primary, Shoushtari, Alexander N., primary, Callahan, Margaret K., primary, Chapman, Paul B., primary, Wolchok, Jedd D., primary, Subrahmanyam, Priyanka B., primary, Maecker, Holden T., primary, Panageas, Katherine S., primary, and Barker, Christopher A., primary
- Published
- 2023
- Full Text
- View/download PDF
35. Supplemental Table 3 from A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma
- Author
-
Postow, Michael A., primary, Knox, Susan J., primary, Goldman, Debra A., primary, Elhanati, Yuval, primary, Mavinkurve, Vikram, primary, Wong, Phillip, primary, Halpenny, Darragh, primary, Reddy, Sunil K., primary, Vado, Kenya, primary, McCabe, Danielle, primary, Ramirez, Kristen Aufiero, primary, Macri, Mary, primary, Schwarzenberger, Paul, primary, Ricciardi, Toni, primary, Ryan, Aileen, primary, Venhaus, Ralph, primary, Momtaz, Parisa, primary, Shoushtari, Alexander N., primary, Callahan, Margaret K., primary, Chapman, Paul B., primary, Wolchok, Jedd D., primary, Subrahmanyam, Priyanka B., primary, Maecker, Holden T., primary, Panageas, Katherine S., primary, and Barker, Christopher A., primary
- Published
- 2023
- Full Text
- View/download PDF
36. Data from Peptide-Loaded Langerhans Cells, Despite Increased IL15 Secretion and T-Cell Activation In Vitro, Elicit Antitumor T-Cell Responses Comparable to Peptide-Loaded Monocyte-Derived Dendritic Cells In Vivo
- Author
-
Romano, Emanuela, primary, Rossi, Marco, primary, Ratzinger, Gudrun, primary, de Cos, Maria-Angeles, primary, Chung, David J., primary, Panageas, Katherine S., primary, Wolchock, Jedd D., primary, Houghton, Alan N., primary, Chapman, Paul B., primary, Heller, Glenn, primary, Yuan, Jianda, primary, and Young, James W., primary
- Published
- 2023
- Full Text
- View/download PDF
37. Data from The Genetic Evolution of Treatment-Resistant Cutaneous, Acral, and Uveal Melanomas
- Author
-
Makohon-Moore, Alvin P., primary, Lipson, Evan J., primary, Hooper, Jody E., primary, Zucker, Amanda, primary, Hong, Jungeui, primary, Bielski, Craig M., primary, Hayashi, Akimasa, primary, Tokheim, Collin, primary, Baez, Priscilla, primary, Kappagantula, Rajya, primary, Kohutek, Zachary, primary, Makarov, Vladimir, primary, Riaz, Nadeem, primary, Postow, Michael A., primary, Chapman, Paul B., primary, Karchin, Rachel, primary, Socci, Nicholas D., primary, Solit, David B., primary, Chan, Timothy A., primary, Taylor, Barry S., primary, Topalian, Suzanne L., primary, and Iacobuzio-Donahue, Christine A., primary
- Published
- 2023
- Full Text
- View/download PDF
38. Tables S1-S8 from The Genetic Evolution of Treatment-Resistant Cutaneous, Acral, and Uveal Melanomas
- Author
-
Makohon-Moore, Alvin P., primary, Lipson, Evan J., primary, Hooper, Jody E., primary, Zucker, Amanda, primary, Hong, Jungeui, primary, Bielski, Craig M., primary, Hayashi, Akimasa, primary, Tokheim, Collin, primary, Baez, Priscilla, primary, Kappagantula, Rajya, primary, Kohutek, Zachary, primary, Makarov, Vladimir, primary, Riaz, Nadeem, primary, Postow, Michael A., primary, Chapman, Paul B., primary, Karchin, Rachel, primary, Socci, Nicholas D., primary, Solit, David B., primary, Chan, Timothy A., primary, Taylor, Barry S., primary, Topalian, Suzanne L., primary, and Iacobuzio-Donahue, Christine A., primary
- Published
- 2023
- Full Text
- View/download PDF
39. Supplementary Figure Legend from Phase II Trial of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with BRAFV600E/K-Mutated Melanoma
- Author
-
Catalanotti, Federica, primary, Solit, David B., primary, Pulitzer, Melissa P., primary, Berger, Michael F., primary, Scott, Sasinya N., primary, Iyriboz, Tunc, primary, Lacouture, Mario E., primary, Panageas, Katherine S., primary, Wolchok, Jedd D., primary, Carvajal, Richard D., primary, Schwartz, Gary K., primary, Rosen, Neal, primary, and Chapman, Paul B., primary
- Published
- 2023
- Full Text
- View/download PDF
40. Supplemental Figure 3 from A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma
- Author
-
Postow, Michael A., primary, Knox, Susan J., primary, Goldman, Debra A., primary, Elhanati, Yuval, primary, Mavinkurve, Vikram, primary, Wong, Phillip, primary, Halpenny, Darragh, primary, Reddy, Sunil K., primary, Vado, Kenya, primary, McCabe, Danielle, primary, Ramirez, Kristen Aufiero, primary, Macri, Mary, primary, Schwarzenberger, Paul, primary, Ricciardi, Toni, primary, Ryan, Aileen, primary, Venhaus, Ralph, primary, Momtaz, Parisa, primary, Shoushtari, Alexander N., primary, Callahan, Margaret K., primary, Chapman, Paul B., primary, Wolchok, Jedd D., primary, Subrahmanyam, Priyanka B., primary, Maecker, Holden T., primary, Panageas, Katherine S., primary, and Barker, Christopher A., primary
- Published
- 2023
- Full Text
- View/download PDF
41. Supplementary Figures S1-S3 from Peptide-Loaded Langerhans Cells, Despite Increased IL15 Secretion and T-Cell Activation In Vitro, Elicit Antitumor T-Cell Responses Comparable to Peptide-Loaded Monocyte-Derived Dendritic Cells In Vivo
- Author
-
Romano, Emanuela, primary, Rossi, Marco, primary, Ratzinger, Gudrun, primary, de Cos, Maria-Angeles, primary, Chung, David J., primary, Panageas, Katherine S., primary, Wolchock, Jedd D., primary, Houghton, Alan N., primary, Chapman, Paul B., primary, Heller, Glenn, primary, Yuan, Jianda, primary, and Young, James W., primary
- Published
- 2023
- Full Text
- View/download PDF
42. Data from Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors
- Author
-
Amaravadi, Ravi K., primary, Hamilton, Kathryn E., primary, Ma, Xiaohong, primary, Piao, Shengfu, primary, Portillo, Armando Del, primary, Nathanson, Katherine L., primary, Carlino, Matteo S., primary, Long, Georgina V., primary, Puzanov, Igor, primary, Xu, Xiaowei, primary, Morrissette, Jennifer J.D., primary, Tsai, Kenneth Y., primary, Flaherty, Keith T., primary, Sosman, Jeffrey A., primary, Goodman, Grant R., primary, McArthur, Grant A., primary, Rustgi, Anil K., primary, Metz, David C., primary, Schuchter, Lynn M., primary, Chapman, Paul B., primary, and Sepulveda, Antonia R., primary
- Published
- 2023
- Full Text
- View/download PDF
43. Figure S4 from The Genetic Evolution of Treatment-Resistant Cutaneous, Acral, and Uveal Melanomas
- Author
-
Makohon-Moore, Alvin P., primary, Lipson, Evan J., primary, Hooper, Jody E., primary, Zucker, Amanda, primary, Hong, Jungeui, primary, Bielski, Craig M., primary, Hayashi, Akimasa, primary, Tokheim, Collin, primary, Baez, Priscilla, primary, Kappagantula, Rajya, primary, Kohutek, Zachary, primary, Makarov, Vladimir, primary, Riaz, Nadeem, primary, Postow, Michael A., primary, Chapman, Paul B., primary, Karchin, Rachel, primary, Socci, Nicholas D., primary, Solit, David B., primary, Chan, Timothy A., primary, Taylor, Barry S., primary, Topalian, Suzanne L., primary, and Iacobuzio-Donahue, Christine A., primary
- Published
- 2023
- Full Text
- View/download PDF
44. Supplemental Figure 1 from Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors
- Author
-
Amaravadi, Ravi K., primary, Hamilton, Kathryn E., primary, Ma, Xiaohong, primary, Piao, Shengfu, primary, Portillo, Armando Del, primary, Nathanson, Katherine L., primary, Carlino, Matteo S., primary, Long, Georgina V., primary, Puzanov, Igor, primary, Xu, Xiaowei, primary, Morrissette, Jennifer J.D., primary, Tsai, Kenneth Y., primary, Flaherty, Keith T., primary, Sosman, Jeffrey A., primary, Goodman, Grant R., primary, McArthur, Grant A., primary, Rustgi, Anil K., primary, Metz, David C., primary, Schuchter, Lynn M., primary, Chapman, Paul B., primary, and Sepulveda, Antonia R., primary
- Published
- 2023
- Full Text
- View/download PDF
45. Supplementary Figure S2 from Quantifying Treatment Benefit in Molecular Subgroups to Assess a Predictive Biomarker
- Author
-
Iasonos, Alexia, primary, Chapman, Paul B., primary, and Satagopan, Jaya M., primary
- Published
- 2023
- Full Text
- View/download PDF
46. Supplemental Table 1 from Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition
- Author
-
Carvajal, Richard D., primary, Lawrence, Donald P., primary, Weber, Jeffrey S., primary, Gajewski, Thomas F., primary, Gonzalez, Rene, primary, Lutzky, Jose, primary, O'Day, Steven J., primary, Hamid, Omid, primary, Wolchok, Jedd D., primary, Chapman, Paul B., primary, Sullivan, Ryan J., primary, Teitcher, Jerrold B., primary, Ramaiya, Nikhil, primary, Giobbie-Hurder, Anita, primary, Antonescu, Cristina R., primary, Heinrich, Michael C., primary, Bastian, Boris C., primary, Corless, Christopher L., primary, Fletcher, Jonathan A., primary, and Hodi, F. Stephen, primary
- Published
- 2023
- Full Text
- View/download PDF
47. Supplemental Figure 1 from A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma
- Author
-
Postow, Michael A., primary, Knox, Susan J., primary, Goldman, Debra A., primary, Elhanati, Yuval, primary, Mavinkurve, Vikram, primary, Wong, Phillip, primary, Halpenny, Darragh, primary, Reddy, Sunil K., primary, Vado, Kenya, primary, McCabe, Danielle, primary, Ramirez, Kristen Aufiero, primary, Macri, Mary, primary, Schwarzenberger, Paul, primary, Ricciardi, Toni, primary, Ryan, Aileen, primary, Venhaus, Ralph, primary, Momtaz, Parisa, primary, Shoushtari, Alexander N., primary, Callahan, Margaret K., primary, Chapman, Paul B., primary, Wolchok, Jedd D., primary, Subrahmanyam, Priyanka B., primary, Maecker, Holden T., primary, Panageas, Katherine S., primary, and Barker, Christopher A., primary
- Published
- 2023
- Full Text
- View/download PDF
48. Supplementary Data from Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Metastatic Melanoma
- Author
-
Solit, David B., primary, Osman, Iman, primary, Polsky, David, primary, Panageas, Katherine S., primary, Daud, Adil, primary, Goydos, James S., primary, Teitcher, Jerrold, primary, Wolchok, Jedd D., primary, Germino, F. Joseph, primary, Krown, Susan E., primary, Coit, Daniel, primary, Rosen, Neal, primary, and Chapman, Paul B., primary
- Published
- 2023
- Full Text
- View/download PDF
49. Supplementary Figure 1B from Phase II Trial of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with BRAFV600E/K-Mutated Melanoma
- Author
-
Catalanotti, Federica, primary, Solit, David B., primary, Pulitzer, Melissa P., primary, Berger, Michael F., primary, Scott, Sasinya N., primary, Iyriboz, Tunc, primary, Lacouture, Mario E., primary, Panageas, Katherine S., primary, Wolchok, Jedd D., primary, Carvajal, Richard D., primary, Schwartz, Gary K., primary, Rosen, Neal, primary, and Chapman, Paul B., primary
- Published
- 2023
- Full Text
- View/download PDF
50. Supplemental Table 1 from A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma
- Author
-
Postow, Michael A., primary, Knox, Susan J., primary, Goldman, Debra A., primary, Elhanati, Yuval, primary, Mavinkurve, Vikram, primary, Wong, Phillip, primary, Halpenny, Darragh, primary, Reddy, Sunil K., primary, Vado, Kenya, primary, McCabe, Danielle, primary, Ramirez, Kristen Aufiero, primary, Macri, Mary, primary, Schwarzenberger, Paul, primary, Ricciardi, Toni, primary, Ryan, Aileen, primary, Venhaus, Ralph, primary, Momtaz, Parisa, primary, Shoushtari, Alexander N., primary, Callahan, Margaret K., primary, Chapman, Paul B., primary, Wolchok, Jedd D., primary, Subrahmanyam, Priyanka B., primary, Maecker, Holden T., primary, Panageas, Katherine S., primary, and Barker, Christopher A., primary
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.